Estimand Framework in Oncology Drug Development: Challenges and Opportunities

Alexei C. Ionan
FDA/CDER/OTS/OB/DBV
24 September 2019
2019 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Disclaimers

• This presentation reflects the views of the author and should not be construed to represent FDA’s views or policies.

• I have nothing to disclose
Acknowledgements

• Kunthel By
• Frank Harrell
• Thomas Gwise
• Tom Permutt
• Donna Przepiorka
• Estelle Russek-Cohen
• Rajeshwari Sridhara
• Jingjing Ye
Outline

• Objectives
• Definitions
• Causal Inference
• Treatment Switching (Cross-Over)
• Beyond Efficacy
• Next Steps
Objectives
Patient Objective

Treatment outcomes with adequate utility

- Therapy efficacy and safety
- Quality-of-life
- Physical, psychological, and social functioning
- Financial toxicity
Regulatory Objective

Substantial evidence

• adequate and well-controlled investigations
• drug will have the effect... prescribed, recommended, or suggested in the labeling

Structured risk-benefit assessment framework

• a consistent and systematic approach to the discussion and regulatory decision-making
• communication of the benefits and risks of new drugs

Title 21. FOOD AND DRUGS Chapter 9. FEDERAL FOOD, DRUG, AND COSMETIC ACT Subchapter V. DRUGS AND DEVICES Part A. Drugs and Devices Section 355. New drugs
Definitions
Estimand

The target of estimation to address the scientific question of interest posed by the trial objective.

1. Population of interest
2. Variable (or endpoint) of interest
3. Specification of how intercurrent events are reflected in the scientific question of interest
4. Population-level summary for the variable
Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure

https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
Key Considerations for Intercurrent Events

• Time to premature treatment discontinuation and the observed assessments for the primary endpoint before and after treatment discontinuation

• The extent of the use of effective rescue medical products after treatment discontinuation or at any other postbaseline times

• Time to follow-up discontinuation
Strategies for Addressing Intercurrent Events

**Treatment Policy:** “The occurrence of the intercurrent event is irrelevant”

**Composite:** “intercurrent event is integrated with one or more other measures of clinical outcome”

**Hypothetical:** “a scenario is envisaged in which the intercurrent event would not occur”

**Principal Stratum:** “principal stratum in which an intercurrent event would not occur.”

**While on Treatment:** “response to treatment prior to the occurrence of the intercurrent event is of interest.”
Intent-to-Treat (ITT) Principle

• All randomized patients
• Preservation of the initial randomization
  • Helps to prevent some bias
  • Provides a “secure foundation for statistical tests”
Causal Inference
### Randomization

- **Causal RR**: \( \frac{P(Y(\text{TRT})=\text{CR})}{P(Y(\text{CTRL})=\text{CR})} \)
- **Observed RR**: \( \frac{P(\text{CR} \mid \text{TRT})}{P(\text{CR} \mid \text{CTRL})} \)
- **Randomization**: \( (Y(\text{CTRL}), Y(\text{TRT})) \perp \text{TRT} \)
- TRT = treatment
- CTRL = control
- CR = Complete Response
- PD = Progressive Disease
- \( \perp = \) Independent

<table>
<thead>
<tr>
<th>Group</th>
<th>Y</th>
<th>Y(CTRL)</th>
<th>Y(TRT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTRL</td>
<td>CR</td>
<td>CR</td>
<td>?</td>
</tr>
<tr>
<td>CTRL</td>
<td>PD</td>
<td>PD</td>
<td>?</td>
</tr>
<tr>
<td>CTRL</td>
<td>PD</td>
<td>PD</td>
<td>?</td>
</tr>
<tr>
<td>TRT</td>
<td>CR</td>
<td>?</td>
<td>CR</td>
</tr>
<tr>
<td>TRT</td>
<td>CR</td>
<td>?</td>
<td>CR</td>
</tr>
<tr>
<td>TRT</td>
<td>PD</td>
<td>?</td>
<td>PD</td>
</tr>
</tbody>
</table>
Which causal inference framework?

• “Some form of counterfactual reasoning, such as the “potential outcomes” approach championed by Rubin, appears unavoidable, but this typically yields “answers” that are sensitive to arbitrary and untestable assumptions.” (Dawid et al., 2016)

• What is identifiable and estimable? (Greenland and Robins, 2009; Maclaren and Nicholson, 2019)
Hidden Causal Assumptions Lead to Erroneous Causal Claims

• Treatment randomization allows identification of the marginal $Y(\text{TRT})$ and $Y(\text{CTRL})$ distributions (Rubin, 1978).

• Treatment randomization does not identify the joint potential-outcome $(Y(\text{TRT}), Y(\text{CTRL}))$ distribution (e.g. Dawid, 2000).

• No complete $(Y(\text{TRT}), Y(\text{CTRL}))$ pair is observed. We cannot verify harm, benefit, or no effect in any individual from the data alone.

• We only observe marginal averages over these individuals (e.g. Greenland et al., 2019).
Measured and Unmeasured Covariates

Can we identify relevant covariates?
• Measured covariates must be sufficient to block all backdoor paths from treatment to outcome (Pearl, 2009).
• Adjusting for all measured covariates is not the answer: adjusting for factors affected by the exposure may introduce bias (e.g. Weinberg, 1993).

Unknown Unknowns
• What about unmeasured covariates? What magnitude of association is needed to sufficiently reduce the treatment effect? (e.g. E-values and related methods with minimal assumptions).
Treatment Switching
Non-Radiographic Progression

Subsequent Anti-Cancer Therapy
- (Not) Approved
- Same/Other Group

Last Response Assessment

Intercurrent Event

Complete Response

Non-Radiographic Progression

Partial Response

Progressive Disease

Last Response Assessment → Intercurrent Event → (Not) Approved/Same/Other Group

Complete Response → Non-Radiographic Progression

Partial Response → Progressive Disease
Randomization

Group A
Experimental

Group B
Control

PR

PD

Switch to experimental therapy
Study Conduct and Design, Equipoise

- Interim PFS analysis
- Intolerance
- Clinical progression
- Protocol Violations
Some Statistical Methods

- Censoring
- **Inverse Probability of Censoring Weighting** (IPCW) (e.g. Robins, 1993)
- **Rank Preserving Structural Failure Time models** (RPSFT) (e.g. Robins and Tsiatis, 1991)
- **Two-stage methods** (e.g. Robins and Greenland, 1994; Yamaguchi and Ohashi, 2004; Latimer et al., 2014)

This is not a comprehensive list.
This is NOT the FDA endorsement of methods listed above.
“Given the limitations associated with the adjustment methods, the ITT analysis should always be presented.”

Consider

• Characteristics of the trial
• The switching mechanism
• The treatment effect
• Data requirements/availability and adjustment method outputs
EMA Guidance on Treatment Switching

13 December 2018
EMA/845963/2018
Human Medicines Research and Development Support Division

Question and answer on adjustment for cross-over in estimating effects in oncology trials

<table>
<thead>
<tr>
<th>Agreed by Biostatistics Working Party</th>
<th>November 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption by CHMP</td>
<td>13 December 2018</td>
</tr>
</tbody>
</table>
EMA Guidance on Treatment Switching

• Assumptions of the adjustment methods can in principle not be proven to be true
• A positive result from an analysis adjusted for cross-over cannot be used to rescue a trial
• May only be useful for regulatory purposes as supportive or sensitivity analyses
Beyond Efficacy
Beyond Efficacy

• Safety (e.g. Unkel et al., 2018)
• Patient-Reported Outcomes (FDA-ASCO Public Workshop 2019)
• Benefit-Risk
• Real World Evidence
Communication of Results

Statistical Analysis Plan

- Target Study Population
- Variable (Endpoint) of Interest
- Intercurrent Events
- Population Level Summary

Estimand

PRO Research Objective
BENEFIT-RISK ASSESSMENT IN DRUG REGULATORY DECISION-MAKING

Draft PDUFA VI Implementation Plan (FY 2018-2022)
Next Steps
ICH E9 R1 Addendum

“gives a framework for discussing certain interesting estimands... but it is not clear whether methods for estimating them are presently practical in a regulatory environment” (Permutt, 2019)
Transparent Subjectivity

(a) statistical work in which the assumptions and judgments are fully in view, for everyone to consider and critique, and in which sensitivity analysis reveals stability or fragility of conclusions with respect to the assumptions and judgments.

(b) analyses disciplined by both coherence and calibration in a way that helps us, and others working with us, to make good predictions of observables.
Practical Considerations: Pre-Specification

Explicitly specify in protocol and SAP

- Potential **intercurrent events**
- All **censoring** and event rules
- Statistical **methods** for addressing intercurrent events
- All **assumptions** of statistical methods
- If any assumptions can be assessed and which **sensitivity** analyses will be used to assess each assumption
Practical Considerations: Causal Inference

• Is the quantify of interest identifiable and estimable?
• What assumptions are needed?
• Is a clinical interpretation of a statistical method output meaningful?
• Can relevant covariates be identified at a design stage?
• Is utility of measuring these covariates favorable?
• How may potential unmeasured covariates change conclusions and interpretation of the results?
• Are regulatory agencies in alignment with the proposed statistical plan?
Practical Considerations: Treatment Switching

• Address treatment switching at the **design stage**
• Adequately align **enrollment** in trials intended for accelerated and regular approval
• Explicitly state if treatment switching is allowed and under what **conditions** in the protocol and SAP
• Ensure adequate **data collection** to support the proposed analyses
• Minimize **protocol violations** by investigators
Opportunities

• What is the relevant scientific question? Can existing statistical methods provide results with **meaningful clinical interpretation**? What scientific questions do existing methods really answer?

• Develop methods that rely on **minimal assumptions**

• Identify conditions **when ITT analysis is suboptimal**

• Collaborate with clinicians by disease area to determine:
  • **Populations**: identify key populations of interest
  • **Variables**: identify clinically meaningful outcomes
  • **Intercurrent events**: identify all potential intercurrent events and the best methods to address them